Please ensure Javascript is enabled for purposes of website accessibility

If You Invested $10,000 in BioNTech in January, This Is How Much You'd Have Now

By Jason Hawthorne - Updated Jan 16, 2021 at 9:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

You have to take some risk if you expect to get the reward.

Developing a vaccine in record time might seem foreseeable in hindsight. But if you didn't buy one of the biotech stocks that has come through, don't beat yourself up. Sure, buying $10,000 worth of shares in BioNTech (BNTX -4.81%) at the beginning of the year would have you sitting on $30,000 right now.

But most people couldn't have foreseen a global pandemic and the first-ever vaccine using messenger RNA. Let's see what your returns might have looked like if you decided to buy shares as you got more information throughout the year.

Stack of four blocks with three of them labeled high, medium, and low under a fourth block labeled risk.

Image source: Getty Images

March 17

BioNTech announced that development of its vaccine -- BNT162b2 -- was progressing rapidly, and it would begin clinical testing in late April. Although the stock gyrated wildly, $10,000 worth of shares purchased at the close would be worth a little more than $15,000.

July 22

Management announced that they, along with partner Pfizer (PFE 1.50%), had signed an agreement with the U.S. government to supply up to 600 million doses of the vaccine. They also reiterated the timeline, including a plan to seek regulatory approval as early as October. Management estimated up to 100 million doses would be available by the end of the year. The $10,000 worth of shares purchased at the close would be worth about $9,750 now.

December 11

About a month ago, the partners developed the first vaccine authorized in the U.S. to prevent COVID-19. At this point, there was a light at the end of the tunnel, and most of the relevant information for investors was known. The vaccine was authorized, and agreements were in place to deliver massive numbers of doses. If you bought $10,000 worth of shares that day, they would now be worth about $8,000.

Waiting for information has its cost

It makes sense that investors' returns would be greater if they bought shares with less information. That's the nature of investing. Of course, those early investors were also taking the chance that the vaccine wouldn't succeed. It's a good illustration of how, even in a pandemic, stock market returns are tied to how much risk you take.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$151.20 (-4.81%) $-7.64
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.67 (1.50%) $0.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.